Since our inception in 2004, our research and service capacity has expanded to the entire new drug discovery and development pipeline, including early discovery, preclinical testing, process development, cGMP manufacturing, phase 1-III clinical trials.
As a global company, we have more than 200 talented and well-trained scientists located in different continents working closely with partners from the entire world to develop and produce medicines of tomorrow. Specifically, we are the established leading expert in TCR and CAR T&NK cell immune therapy development, as we offer the one-stop custom services that cover the entire new drug development pipeline. Additionally, we also offer an exclusive line of ready-to-use TCR and CAR T&NK cell construction products, such as virus packaging, purification, expansion and titer determination kits. Furthermore, we have built up a unique unparalleled CAR construction and production platform for all four CAR generations.
With the exponentially increased demand in modern novel medicine, the CAR and TCR immune cell therapy has been one of the most promising approaches for target-specific cancer treatment. With our integrated global resources in all aspects, we provide one-stop full CAR T/NK Cell therapy development service, including early non-clinical research, process development, pre-clinical animal model testing, cGMP manufacturing, and phase I-III clinical trials.